Anaphylaxis and cardiovascular diseases: A dangerous liaison

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 4, 2014, Pages 309-315

  Triggiani, Massimo ^a   Montagni, Marcello ^b   Parente, Roberta ^a   Ridolo, Erminia ^b  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

anaphylaxis; heart; mast cell; mediators

Indexed keywords

CARDIOVASCULAR AGENT; HISTAMINE; PROSTAGLANDIN; THROMBOCYTE ACTIVATING FACTOR;

ALLERGIC DISEASE; ANAPHYLAXIS; ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYMPTOM; CARDIOVASCULAR SYSTEM; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY VASCULAR RESISTANCE; DISEASE SEVERITY; HEART ARREST; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; KOUNIS SYNDROME; MAST CELL; MAST CELL ACTIVATION SYNDROME; MASTOCYTOSIS; MEDIATOR RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TAKOTSUBO CARDIOMYOPATHY; COMPLICATION; IMMUNOLOGY; INFLAMMATION;

ANAPHYLAXIS; CARDIOVASCULAR DISEASES; HISTAMINE; HUMANS; INFLAMMATION; MASTOCYTOSIS; PLATELET ACTIVATING FACTOR; PROSTAGLANDINS;

EID: 84903791264     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000071     Document Type: Review

References (69)

1. Lawson JA, Senthilselvan A. Asthma epidemiology: has the crisis passed? Curr Opin Pulm Med 2005; 11:79-84.
2. Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367-377.
3. Lieberman P, Camargo CA Jr, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97:596-602.
4. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285-290.
5. Gibbison B, Sheikh A, McShane P, et al. Anaphylaxis admissions to UK critical care units between 2005 and 2009. Anaesthesia 2012; 67:833-839.
6. Low I, Stables S. Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005. Pathology 2006; 38:328-332.
7. Marone G, Bova M, Detoraki A, et al. The human heart as a shock organ in anaphylaxis. Novartis Found Symp 2004; 257:133-149.
8. Golden DB. What is anaphylaxis? Curr Opin Allergy Clin Immunol 2007; 7:331-336.
9. Lombardi A, Vandelli R, Cerè E, Di Pasquale G. Silent acute myocardial infarction following a wasp sting. Ital Heart J 2003; 4:638-641.
10. Wagdi P, Mehan VK, Bürgi H, Salzmann C. Acute myocardial infarction after wasp stings in a patient with normal coronary arteries. Am Heart J 1994; 128:820-823.
11. Mueller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337-341.
12. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2-S24.
13. Patella V, Marinò I, Lamparter B, et al. Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J Immunol 1995; 154:2855-2865.
14. Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 (Suppl 1):7-11.
15. Vigorito C, Giordano C, De Caprio A, et al. Effects of histamine on coronary hemodynamics in humans: role of H1 and H2 receptors. J Am Coll Cardiol 1987; 10:1207-1213.
16. Vigorito C, Poto S, Picotti GB, et al. Effect of activation of the H1 receptor on coronary hemodynamics in man. Circulation 1986; 73:1175-1182.
17. Steffel J, Akhmedov A, Greutert H, et al. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 2005; 112:341-349.
18. MaroneG, Giordano A, Cirillo R, et al. Cardiovascular and metabolic effects of peptide leukotrienes in man. Ann N Y Acad Sci 1988; 524:321-333.
19. Vigorito C, Giordano A, Cirillo R, et al. Metabolic and hemodynamic effects of peptide leukotriene C4 and D4 in man. Int J Clin Lab Res 1997; 27:178-184.
20. Sanak M, Dropinski J, Sokolowska B, et al. Pharmacological inhibition of leukotriene biosynthesis: effects on the heart conductance. J Physiol Pharmacol 2010; 61:53-58.
21. Hattori Y, Levi R. Effect of PGD2 on cardiac contractility: a negative inotropism secondary to coronary vasoconstriction conceals a primary positive inotropic action. J Pharmacol Exp Ther 1986; 237:719-724.
22. Golino P, Ambrosio G, Ragni M, et al. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation. Circulation 1993; 88:1205-1214.
23. Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1995; 1254:231-249.
24. Triggiani M, Schleimer RP, Warner JA, Chilton FH. Differential synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells. J Immunol 1991; 147:660-666.
25. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80:1669-1699.
26. Braquet P, Rola-Pleszczynski M. The role of PAF in immunological responses: a review. Prostaglandins 1987; 34:143-148.
27. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92:1084-1088.
28. Choi IH, Ha TY, Lee DG, et al. Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor. Clin Exp Immunol 1995; 100:390-394.
29. Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28-35.
30. Brown AF, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108:861-866.
31. Worm M, Edenharter G, Ruëff F, et al. Symptom profile and risk factors of anaphylaxis in Central Europe. Allergy 2012; 67:691-698.
32. Beyer K, EckermannO, Hompes S, et al. Anaphylaxis in an emergency setting: elicitors, therapy and incidence of severe allergic reactions. Allergy 2012; 67:1451-1456.
33. Gelincik A, Demirtürk M, Y?lmaz E, et al. Anaphylaxis in a tertiary adult allergy clinic: a retrospective review of 516 patients. Ann Allergy Asthma Immunol 2013; 110:96-100.
34. Park HJ, Kim SH. Factors associated with shock in anaphylaxis. Am J Emerg Med 2012; 30:1674-1678.
35. Simons FE, Ardusso LR, Bilò MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4:13-37.
36. Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252-257.
37. Sasvary T, Müller U. Fatalities from insect stings in Switzerland 1978 to 1987. Schweiz Med Wochenschr 1994; 124:1887-1894.
38. Yilmaz R, Yuksekbas O, Erkol Z, et al. Postmortem findings after anaphylactic reactions to drugs in Turkey. Am J Forensic Med Pathol 2009; 30:346-349.
39. Caviglia AG, Passalacqua G, Senna G. Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J Allergy Clin Immunol 2010; 125:1171.
40. Lee S, Hess EP, Nestler DM, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 2013; 131:1103-1108.
41. Zuberbier T, Bachert C, Bousquet PJ, et al. J. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010; 65:1525-1530.
42. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1-S55.
43. Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase: a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-1054.
44. Ruëff F, Przybilla B, Biló MB, et al., European Academy of Allergy and Clinical Immunology Interest Group. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126:105-111.
45. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606-610.
46. Hepner MJ, Ownby DR, Anderson JA, et al. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol 1990; 86:407-411.
47. Ünsel M, Ardeniz FO, Mete N, Sin AZ. Are ACE inhibitors really safe in the patients receiving venom immunotherapy? Asthma Allergy Immunol 2012; 10:100-103.
48. Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003; 112:1008-1009.
49. Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992; 340:908.
50. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101:426-430.
51. Pfister CW, Plice SG. Acute myocardial infarction during a prolonged allergic reaction to penicillin. Am Heart J 1950; 40:945-947.
52. Kounis NG, Zavras GM. Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 1991; 45:121-128.
53. Kounis NG. Coronary hypersensitivity disorder: the Kounis syndrome. Clin Ther 2013; 35:563-571.
54. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109:701-705.
55. Chen JP, Hou D, Pendyala L, et al. Drug-eluting stent thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited. JACC Cardiovasc Interv 2009; 2:583-593.
56. Greif M, Pohl T, Oversohl N, et al. Acute stent thrombosis in a sirolimus eluting stent after wasp sting causing acute myocardial infarction: a case report. Cases J 2009; 12:7800.
57. Ridolo E, Olivieri E, Montagni M, et al. Type I variant of Kounis syndrome secondary to wasp sting. Ann Allergy Asthma Immunol 2012; 109:79-81.
58. Marcoux V, Nosib S, Bi H, Brownbridge B. Intraoperative myocardial infarction: Kounis, syndrome provoked by latex allergy. BMJ Case Rep 2013; pii: bcr2012007581. doi: 10.1136/bcr-2012-007581.
59. Barbarroja-Escudero J, Rodriguez-Rodriguez M, Sanchez-Gonzalez MJ, et al. Anisakis simplex: a new etiological agent of Kounis syndrome. Int J Cardiol 2013; 167:e187-e189.
60. Josefsson J, Fröbert O. Losartan-induced coronary artery spasm. BMJ Case Rep 2012; pii: bcr2012006252. doi: 10.1136/bcr-2012-006252.
61. Saylan B, Cevik A, Firat C. Kounis syndrome, a cause of chest pain to keep in mind, may be associated with E148Q mutation. Hong Kong J Emerg Med 2012; 19:278-282.
62. Yanagawa Y, Nishi K, Tomiharu N, Kawaguchi T. A case of takotsubo cardiomyopathy associated with Kounis syndrome. Int J Cardiol 2009; 132:e65-e67.
63. Vultaggio A, Matucci A, Del Pace S, et al. Tako-Tsubo-like syndrome during anaphylactic reaction. Eur J Heart Fail 2007; 9:209-211.
64. Winogradow J, Geppert G, Reinhard W, et al. Tako-Tsubo cardiomyopathy after administration of intravenous epinephrine during an anaphylactic reaction. Int J Cardiol 2011; 147:309-311.
65. Fassio F, Almerigogna F. Tako-Tsubo cardiomyopathy or Kounis syndrome: finding differences and similarities to answer the question. Intern Emerg Med 2013; 8:637-638.
66. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 125:1269-1278.
67. Reiter N, Reiter M, Altrichter S, et al. Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet 2013; 382:1380.
68. González-de-Olano D, Matito A, Sánchez-López P, et al. Mast cell-related disorders presenting with Kounis syndrome. Int J Cardiol 2012; 161:56-58.
69. Ridolo E, Triggiani M, Montagni M, et al. Mastocytosis presenting as cardiac emergency. Intern Emerg Med 2013; 8:749-752.